Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Clinical uses of dronedarone

Rod Passman, MD, MSCE
Elsa-Grace Giardina, MD, MS, FACC, FACP, FAHA
Section Editor
Mark S Link, MD
Deputy Editor
Brian C Downey, MD, FACC


Dronedarone, a noniodinated congener of amiodarone, was developed as an antiarrhythmic agent for the maintenance of sinus rhythm in patients with atrial fibrillation. Because of the molecular and structural differences between dronedarone and amiodarone, in particular the deletion of the iodine molecules which are present in amiodarone, researchers have hypothesized that dronedarone will have fewer thyroid and pulmonary effects than amiodarone. Clinical trials have shown the clinical use and short-term safety (up to 21 months) of dronedarone for the maintenance of sinus rhythm following cardioversion in patients with atrial fibrillation [1]. The efficacy and tolerability of dronedarone in children and adolescents aged <18 years have not been established.

A review of the pharmacology of dronedarone, its clinical uses, adverse effects, and drug interactions will be presented here. The clinical uses and toxicities of amiodarone and the choice of antiarrhythmic agents in the management of atrial fibrillation are discussed separately. (See "Clinical uses of amiodarone" and "Major side effects of amiodarone" and "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations".)


Dronedarone is a class III antiarrhythmic agent and a potent blocker of multiple intracardiac ion channels with many electrophysiological properties in common with amiodarone (table 1) [2]. Like amiodarone, dronedarone has antiadrenergic (ie, beta blocking) properties and inhibits multiple transmembrane potassium currents, including the delayed rectifier current, the ultra-rapid delayed rectifier current, the inward rectifier current, and the transient outward current. In addition, dronedarone blocks inward depolarizing sodium and L-type calcium currents.

Limited pharmacokinetic data are available for dronedarone and are derived primarily from data in the United States Food and Drug Administration (FDA) prescribing information and from data in the FDA briefing document [3]. Dronedarone is approximately 70 to 94 percent absorbed after oral administration, but its absolute bioavailability is only approximately 15 percent due to significant first pass metabolism. Peak plasma concentrations are achieved within three to six hours. However, there is a significant food effect which increases plasma dronedarone concentrations between two- and threefold when the drug is taken with food [3]. Following the initiation of dronedarone 400 mg twice daily, steady-state plasma concentrations are reached within four to eight days [4].

The clearance of dronedarone is principally nonrenal, with a terminal half-life of approximately 24 hours [3]. This is markedly shorter than the half life of amiodarone, which has an effective half-life of up to 50 days. Dronedarone is highly bound to plasma proteins and is not associated with significant tissue accumulation. Therefore, it has been postulated that systemic side effects secondary to long-term usage of the drug, such as liver toxicity, pulmonary fibrosis, or thyroid dysfunction will be minimized in comparison to amiodarone. However, long-term toxicity data are not yet available.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 22, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357:987.
  2. Varró A, Takács J, Németh M, et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol 2001; 133:625.
  3. MULTAQ Dronedarone tablets prescribing information products.sanofi.us/Multaq/Multaq.pdf.
  4. Hoy SM, Keam SJ. Dronedarone. Drugs 2009; 69:1647.
  5. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007; 64:785.
  6. Damy T, Pousset F, Caplain H, et al. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol 2004; 18:113.
  7. Hohnloser SH, Halperin JL, Camm AJ, et al. Interaction between digoxin and dronedarone in the PALLAS trial. Circ Arrhythm Electrophysiol 2014; 7:1019.
  8. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008; 156:527.e1.
  9. Vallakati A, Chandra PA, Pednekar M, et al. Dronedarone-induced digoxin toxicity: new drug, new interactions. Am J Ther 2013; 20:e717.
  10. Dorian P. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther 2010; 15:15S.
  11. Dronedarone tablets. European Medicines Agency (EMA) Summary of product characteristics. Last updated October 29, 2014. European Medicines Agency. www.ema.europa.eu/ema/index.jsp.
  12. Shirolkar SC, Fiuzat M, Becker RC. Dronedarone and vitamin K antagonists: a review of drug-drug interactions. Am Heart J 2010; 160:577.
  13. Patel C, Yan GX, Kowey PR. Dronedarone. Circulation 2009; 120:636.
  14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875.
  15. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64:e1.
  16. Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003; 24:1481.
  17. Guerra F, Hohnloser SH, Kowey PR, et al. Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. Clin Cardiol 2014; 37:717.
  18. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21:597.
  19. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J 2016.
  20. Page RL, Connolly SJ, Crijns HJ, et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol 2011; 107:1019.
  21. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668.
  22. Pisters R, Hohnloser SH, Connolly SJ, et al. Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace 2014; 16:174.
  23. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365:2268.
  24. Friberg L. Safety of dronedarone in routine clinical care. J Am Coll Cardiol 2014; 63:2376.
  25. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358:2678.
  26. Chatterjee S, Ghosh J, Lichstein E, et al. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012; 110:607.
  27. Shaaraoui M, Freudenberger R, Levin V, Marchlinski FE. Suppression of ventricular tachycardia with dronedarone: a case report. J Cardiovasc Electrophysiol 2011; 22:201.
  28. Kao DP, Hiatt WR, Krantz MJ. Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting. Pharmacotherapy 2012; 32:767.
  29. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/09/news_detail_001344.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1. (Accessed on September 22, 2011).